MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma

Multiple myeloma (MM) patients with the t(14;16) translocation have a poor prognosis, and unlike other molecular subgroups, their outcome has not improved with the introduction of bortezomib (Bzb). The mechanism underlying innate resistance of MM to Bzb is unknown. In the present study, we have inve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Qiang, Ya-Wei, Ye, Shiqiao, Chen, Yu, Buros, Amy F., Edmonson, Ricky, van Rhee, Frits, Barlogie, Bart, Epstein, Joshua, Morgan, Gareth J., Davies, Faith E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5179331/
https://ncbi.nlm.nih.gov/pubmed/27793878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-706077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados